These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32451263)

  • 1. Efficacy of belimumab in Primary Sjögren's syndrome: A systematic review.
    Álvarez-Rivas N; Sang-Park H; Díaz Del Campo P; Fernández-Castro M; Corominas H; Andreu JL; Navarro-Compán V
    Reumatol Clin (Engl Ed); 2021 Mar; 17(3):170-174. PubMed ID: 32451263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.
    Mariette X; Seror R; Quartuccio L; Baron G; Salvin S; Fabris M; Desmoulins F; Nocturne G; Ravaud P; De Vita S
    Ann Rheum Dis; 2015 Mar; 74(3):526-31. PubMed ID: 24347569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of belimumab given for 12 months in primary Sjögren's syndrome: the BELISS open-label phase II study.
    De Vita S; Quartuccio L; Seror R; Salvin S; Ravaud P; Fabris M; Nocturne G; Gandolfo S; Isola M; Mariette X
    Rheumatology (Oxford); 2015 Dec; 54(12):2249-56. PubMed ID: 26242856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of biological DMARDs modulating B cells in primary Sjögren's syndrome: Systematic review and meta-analysis.
    Letaief H; Lukas C; Barnetche T; Gaujoux-Viala C; Combe B; Morel J
    Joint Bone Spine; 2018 Jan; 85(1):15-22. PubMed ID: 28673789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive Function in Primary Sjögren's Syndrome: A Systematic Review.
    Manzo C; Martinez-Suarez E; Kechida M; Isetta M; Serra-Mestres J
    Brain Sci; 2019 Apr; 9(4):. PubMed ID: 30991679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren's syndrome: results of the BELISS study.
    Seror R; Nocturne G; Lazure T; Hendel-Chavez H; Desmoulins F; Belkhir R; Ravaud P; Benbijja M; Poirier-Colame V; Taoufik Y; Mariette X
    Arthritis Res Ther; 2015 Sep; 17(1):241. PubMed ID: 26336930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SER recommendations on the use of biological drugs in primary Sjögren's syndrome.
    Andréu Sánchez JL; Fernández Castro M; Del Campo Fontecha PD; Corominas H; Narváez García FJ; Gómez de Salazar JR; Rua-Figueroa Í; Abad Hernández MÁ; Álvarez Rivas MN; Montes JDP; Francisco Hernández FM; Gantes Pedraza MÁ; Greco Merino MG; Hernández MV; Navarro Compán MV; Solarte JAP; Romero Bueno FI; Park HS; Sivera Mascaró F
    Reumatol Clin (Engl Ed); 2019; 15(6):315-326. PubMed ID: 30683506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
    Liu X; Li X; Li X; Li Z; Zhao D; Liu S; Zhang M; Zhang F; Zhu P; Chen J; Wei W; Lin B; Zhou Y; Chen J; Pang Y; Zhang L; Sun X; Yu Z; Jia Y; Wang J; Sun W; Chiu F; Pang L; Wang G
    Clin Rheumatol; 2019 Mar; 38(3):657-664. PubMed ID: 30280368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome.
    Pontarini E; Fabris M; Quartuccio L; Cappeletti M; Calcaterra F; Roberto A; Curcio F; Mavilio D; Della Bella S; De Vita S
    Rheumatology (Oxford); 2015 Aug; 54(8):1429-34. PubMed ID: 25740829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab Effectiveness and Safety for Treating Primary Sjögren's Syndrome (pSS): Systematic Review and Meta-Analysis.
    Souza FB; Porfírio GJ; Andriolo BN; Albuquerque JV; Trevisani VF
    PLoS One; 2016; 11(3):e0150749. PubMed ID: 26998607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry.
    Oni C; Mitchell S; James K; Ng WF; Griffiths B; Hindmarsh V; Price E; Pease CT; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Hunter J; Gupta M; McLaren J; Cooper A; Regan M; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman SJ;
    Rheumatology (Oxford); 2016 Mar; 55(3):544-52. PubMed ID: 26510429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?
    Devauchelle-Pensec V; Gottenberg JE; Jousse-Joulin S; Berthelot JM; Perdriger A; Hachulla E; Hatron PY; Puechal X; Le Guern V; Sibilia J; Chiche L; Goeb V; Vittecoq O; Larroche C; Fauchais AL; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Dieudé P; Pers JO; Cornec D; Seror R; Mariette X; Nowak E; Saraux A
    PLoS One; 2015; 10(9):e0133907. PubMed ID: 26368934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
    De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
    Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Go Ask Your Patients! PSS-QoL Reported Perception of Dryness Correlates With Lacrimal and Salivary Flow in Primary Sjögren's Syndrome.
    Lackner A; Bosch P; Zenz S; Horwath-Winter J; Rabensteiner DF; Hermann J; Graninger W; Stradner MH
    Front Med (Lausanne); 2021; 8():660580. PubMed ID: 33937295
    [No Abstract]   [Full Text] [Related]  

  • 15. Protocolised odontological assessment of patients with primary Sjögren's syndrome.
    Fernández Castro M; López-Pintor RM; Serrano J; Ramírez L; Sanz M; Andreu JL; Muñoz Fernández S;
    Reumatol Clin (Engl Ed); 2021 Jan; 17(1):25-31. PubMed ID: 30745279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of primary Sjögren's syndrome in male and paediatric populations.
    Virdee S; Greenan-Barrett J; Ciurtin C
    Clin Rheumatol; 2017 Oct; 36(10):2225-2236. PubMed ID: 28735431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. World Workshop on Oral Medicine VII: Immunobiologics for salivary gland disease in Sjögren's syndrome: A systematic review.
    Gueiros LA; France K; Posey R; Mays JW; Carey B; Sollecito TP; Setterfield J; Woo SB; Culton D; Payne AS; Lodi G; Greenberg MS; De Rossi S
    Oral Dis; 2019 Jun; 25 Suppl 1(Suppl 1):102-110. PubMed ID: 31140693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
    Shao Q; Wang S; Jiang H; Liu L
    Scand J Rheumatol; 2021 Mar; 50(2):143-152. PubMed ID: 33118847
    [No Abstract]   [Full Text] [Related]  

  • 19. A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.
    Kedor C; Zernicke J; Hagemann A; Gamboa LM; Callhoff J; Burmester GR; Feist E
    Clin Rheumatol; 2016 Sep; 35(9):2203-10. PubMed ID: 27470087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral health-related quality of life in primary Sjögren's syndrome.
    Fernández-Martínez G; Zamora-Legoff V; Hernández Molina G
    Reumatol Clin (Engl Ed); 2020; 16(2 Pt 1):92-96. PubMed ID: 29754950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.